yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News

2008 West
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
Red Hat
The Opening of Virtualization
User Environment Management – The Third Layer of the Desktop
Cloud Computing for Business Agility
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Return on Assests: Bringing Visibility to your SOA Strategy
Managing Hybrid Endpoint Environments
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
How Can AJAX Improve Homeland Security?
Beyond Widgets: What a RIA Platform Should Offer
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
Top Links You Must Click On

XBiotech Receives Fast Track Designation from FDA for True Human™ Monoclonal Antibody Therapy Targeting Inflammatory Cytokine IL-1a for Restenosis
First Therapy for Treatment of Restenosis and Vascular Disease

AUSTIN, Texas, Jan. 3, 2013 /PRNewswire/ -- XBiotech, a privately held biotechnology company, announced today that the company has been granted Fast Track designation by the FDA for its therapeutic monoclonal antibody MABp1 (CV-18C3) as a treatment to reduce the need for re-intervention after superficial femoral artery (SFA) revascularization. Strong positive results from a recent Phase II study demonstrated that treatment with MABp1 resulted in prolonged patency of the SFA and reduction in Major Adverse Cardiovascular Events (MACE), indicating both a local treatment effect, as well as impact on underlying vascular disease.  


This is the second FDA Fast Track Designation secured by XBiotech for lead candidate MABp1. The first FDA Fast Track Designation was received by the Company at the end of last year for Xilonix™ (MABp1) therapy for the treatment of advanced cancer with associated cachexia. 

According to the American Heart Association, heart disease, stroke, and related vascular deaths are by far the leading causes of disease and death in the United States.1 The economic impact from heart disease and stroke in the United States for 2007 (including health expenditures and lost productivity) was $286 billion – higher than any other disease.2 Chronic inflammation in the blood vessel wall results in progression of arterial disease such as atherosclerois. Blocking chronic inflammations offers the potential to halt or even reverse the progression of atherosclerois, as well as reduce the impact of heart attack and stroke. 

"We appreciate the FDA's review of our clinical results and their support for moving this program forward as quickly as possible for patients," said Michael Stecher, M.D., Medical Director of XBiotech.  "Blocking chronic inflammation with a therapeutic antibody has the potential to provide an important treatment option for endovascular surgeons and interventional cardiologists who currently have limited or no options for addressing restenosis or the underlying complications of vascular disease in these patients. We believe MABp1 represents a significant advance in the field, offering new hope to both patients and physicians."

"We are very pleased to receive a second Fast Track Designation from the FDA for our lead compound targeting the inflammatory cytokine IL-1a," said John Simard, president and CEO, of XBiotech. "Using an anti-IL-1a True Human antibody to inhibit vascular inflammation appears to be broadly beneficial to cardiovascular health and could have significant implications in helping to reduce the high costs of healthcare associated not only with restenosis, but overall complications of vascular disease. With the advance of multiple regulatory paths, we are indeed closer to establishing a new medical paradigm - that multiple diseases can be treated through blocking chronic inflammatory processes.

About True Human™ Antibodies
True Human™ antibodies represent the next generation of therapeutic antibodies.  These antibodies are identified using the Company's proprietary platform technology to ensure faithful reproduction of the original human antibody gene.  True Human antibodies are "invisible" to the body's immune system and thus have the potential for better safety, efficacy and patient tolerability compared to earlier generation antibody therapeutics.

About XBiotech
XBiotech is pioneering breakthrough therapies that improve the safety and efficacy of antibody therapeutics. The Company's lead product candidate inhibits chronic sterile inflammation by targeting IL-1a, a master regulator of inflammation. The clinical development program addresses tremendous unmet medical need in multiple disease indications including, acne, psoriasis, cachexia, cancer, type 2 diabetes and cardiovascular disease. XBiotech is also revolutionizing scalable, flexible manufacturing systems for the production of biological therapies.  Using minimal infrastructure and disposable bioreactor technology – to dramatically reduce capital requirements, operating complexity, and lead times - the Company has established a compelling commercialization path for its True Human™ antibody platform.  For more information on how XBiotech is advancing human monoclonal antibody therapy please visit

1 AHA Special Report 2010 - Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction

2 AHA December 14, 2010 - Heart disease, stroke deaths continue to fall but costs remain high

John Simard

Aaron DeLucia
Porter Novelli


About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Enterprise Open Source Magazine Latest Stories . . .
Virgil consists of an open-source encryption library, which implements Cryptographic Message Syntax (CMS) and Elliptic Curve Integrated Encryption Scheme (ECIES) (including RSA schema), a Key Management API, and a cloud-based Key Management Service (Virgil Keys). The Virgil Keys Servic...
Fifty billion connected devices and still no winning protocols standards. HTTP, WebSockets, MQTT, and CoAP seem to be leading in the IoT protocol race at the moment but many more protocols are getting introduced on a regular basis. Each protocol has its pros and cons depending on the n...
Ten short years ago, Apache Hadoop was just a small project deployed on a few machines at Yahoo and within a few years, it had truly become the backbone of Yahoo’s data infrastructure. Additionally, the current Apache Hadoop market is forecasted to surpass $16 billion by 2020. This mi...
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the...
Apache Hadoop is a key technology for gaining business insights from your Big Data, but the penetration into enterprises is shockingly low. In fact, Apache Hadoop and Big Data proponents recognize that this technology has not yet achieved its game-changing business potential. In his ...
The Open Connectivity Foundation (OCF), sponsor of the IoTivity open source project, and AllSeen Alliance, which provides the AllJoyn® open source IoT framework, today announced that the two organizations’ boards have approved a merger under the OCF name and bylaws. This merger will ad...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)!

Advertise on this site! Contact advertising(at)! 201 802-3021

SYS-CON Featured Whitepapers